Arez, A. P., et al. A clonal Plasmodium falciparum population in an isolated outbreak of malaria in the Republic of Cabo Verde. 1998. Parasitology , 118:347-55.
Asua V, Vinden J, Conrad MD, et al. Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda. Antimicrob Agents Chemother. 2019;63(3):e01818-18. Published 2019 Feb 26. doi:10.1128/AAC.01818-18.
Bereczky S, Mårtensson A, Gil JP, Färnert A. Short report: Rapid DNA extraction from archive blood spots on filter paper for genotyping of Plasmodium falciparum. Am J Trop Med Hyg. 2005 Mar;72(3):249-51. PubMed PMID: 15772315.
Boussaroque A, Fall B, Madamet M, Camara C, Benoit N, Fall M, et al. Emergence of mutations in the K13 propeller gene of Plasmodium falciparum solates from Dakar, Senegal, in 2013–2014. Antimicrob Agents Chemother. 2016;60:624–7.
Chico RM, et al. Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis. Trop Med Int Health. 2015;20:1621–1633. doi: 10.1111/tmi.12595.
Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya MR, Havlir DV, et al. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan Children. PLoS ONE. 2014;9:e105690.
Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, Kamya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal PJ. 2014. Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulated drug sensitivity in Ugandan children. J Infect Dis 210:344–353. doi:10.1093/infdis/jiu141.
DePina 2019a. DePina AJ, Niang EHA, Barbosa Andrade AJ, et al. Achievement of malaria pre-elimination in Cape Verde according to the data collected from 2010 to 2016. Malar J. 2018;17(1):236. Published 2018 Jun 19. doi:10.1186/s12936-018-2376-4
DePina 2019b. DePina AJ, Dia AK, de Ascenção Soares Martins A, et al. Knowledge, attitudes and practices about malaria in Cape Verde: a country in the pre-elimination context. BMC Public Health. 2019;19(1):850. Published 2019 Jul 1. doi:10.1186/s12889-019-7130-5.
DePina AJ, Andrade AJB, Dia AK, Moreira AL, Furtado UD, Baptista H, Faye O, Seck I, Niang EHA. Spatiotemporal characterisation and risk factor analysis of malaria outbreak in Cape Verde in 2017. Tropical Medicine and Health 2019; 47: 3.
Desai M, et al. Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight. Clin Infect Dis. 2016;62:323–333. doi: 10.1093/cid/civ881.
Dhingra SK, Gabryszewski SJ, Small-Saunders JL, et al. Global Spread of Mutant PfCRT and Its Pleiotropic Impact on Plasmodium falciparum Multidrug Resistance and Fitness. mBio. 2019;10(2):e02731-18.
Duah NO, Matrevi SA, de Souza DK, et al. Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after the change of anti-malarial drug treatment policy. Malar J. 2013;12:377. Published 2013 Oct 30. doi:10.1186/1475-2875-12-377
Escobar C, Pateira S, Lobo E, et al. Polymorphisms in Plasmodium falciparum K13-propeller in Angola and Mozambique after the introduction of the ACTs. PLoS One. 2015;10(3):e0119215. Published 2015 Mar 19. doi:10.1371/journal.pone.0119215.
Ferreira PE, Holmgren G, Veiga MI, Uhlén P, Kaneko A, Gil JP. Pfmdr1: mechanisms of transport modulation by functional polymorphisms. PLoS One. 2011;6(9):e23875. doi:10.1371/journal.pone.0023875.
Gil JP, Krishna S. pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies. Expert Rev Anti Infect Ther. 2017;15(6):527–543. doi:10.1080/14787210.2017.1313703.
Idowu AO, Oyibo WA, Bhattacharyya S, et al. Rare mutations in Pfmdr1 gene of Plasmodium falciparum detected in clinical isolates from patients treated with anti-malarial drug in Nigeria. Malar J. 2019;18(1):319. Published 2019 Sep 18. doi:10.1186/s12936-019-2947-z
Isozumi R, Uemura H, Kimata I, Ichinose Y, Logedi J, Omar AH, et al. Novel mutations in K13 propeller gene of artemisinin-resistant Plasmodium falciparum. Emerg Infect Dis. 2015;21:490-2.
Kabir, Mohammad Moktadir, et al. Vector control using LLIN/ITN: reduction of malaria morbidity in Bangladesh. Malaria journal, 2014, 13.1: P47.
Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis. 2015;211:1352–5.
Kublin JG, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185:380–388. doi: 10.1086/338566.
Kuo CL, Duan Y, Grady J. Unconditional or conditional logistic regression model for age-matched case-control data?. Front Public Health 2018; 6:57.
Lerch A, Koepfli C, Hofmann NE, et al. Development of amplicon deep sequencing markers and data analysis pipeline for genotyping multi-clonal malaria infections. BMC Genomics. 2017;18(1):864. Published 2017 Nov 13. doi:10.1186/s12864-017-4260-y
Lobo E, de Sousa B, Rosa S, Figueiredo P, Lobo L, Pateira S, Fernandes N, Nogueira F. Prevalence of pfmdr1 alleles associated with artemether-lumefantrine tolerance/resistance in Maputo before and after the implementation of artemisinin-based combination therapy. Malar J. 2014 Aug 6;13:300. doi: 10.1186/1475-2875-13-300. PubMed PMID: 25098280; PubMed Central PMCID:PMC4248432.
Lu F, Culleton R, Zhang M, et al. Emergence of Indigenous Artemisinin-Resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376(10):991–993. doi:10.1056/NEJMc1612765.
SARMMbogo GW, Nankoberanyi S, Tukwasibwe S, Baliraine FN, Nsobya SL, Conrad MD, Arinaitwe E, Kamya M, Tappero J, Staedke SG, Dorsey G, Greenhouse B, Rosenthal PJ. 2014. Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda. Am J Trop Med Hyg 91:54–61. doi:10.4269/ajtmh.13-0647.
Manske M, Miotto O, Campino S, et al. Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature. 2012 Jul 19;487(7407):375-9.
doi: 10.1038/nature11174.
Ménard D, Khim N, Beghain J, et al. A Worldwide Map of Plasmodium falciparum K13-Propeller Polymorphisms. N Engl J Med. 2016;374(25):2453–2464. doi:10.1056/NEJMoa1513137
Ministério da Saúde. Plano estratégico de pré-eliminação do paludismo em Cape Verde, 2014-2017; Cape Verde. 2014;1-97.
Muiruri P, Juma DW, Ingasia LA, et al. Selective sweeps and genetic lineages of Plasmodium falciparum multi-drug resistance (pfmdr1) gene in Kenya. Malar J. 2018;17(1):398. Published 2018 Oct 30. doi:10.1186/s12936-018-2534-8.
Neil P. Analysis of matched case-control studies. BMJ 2016; 352:i969.
Nkhoma S, Nair S, Mukaka M, Molyneux ME, Ward SA, Anderson TJ. Parasites bearing a single copy of the multi-drug resistance gene (pfmdr-1) with wild-type SNPs predominate amongst Plasmodium falciparum isolates from Malawi. Acta Trop. 2009;111:76–81.
Nsobya SL, Kiggundu M, Nanyunja S, Joloba M, Greenhouse B, Rosenthal PJ. In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother. 2010;54:1200–1206. doi: 10.1128/AAC.01412-09.
Ocan 2019a . Ocan M, Akena D, Nsobya S, et al. K13-propeller gene polymorphisms in Plasmodium falciparum parasite population in malaria affected countries: a systematic review of prevalence and risk factors. Malar J. 2019;18(1):60. Published 2019 Mar 7. doi:10.1186/s12936-019-2701-6.
Ocan 2019b Ocan M, Akena D, Nsobya S, et al. Persistence of chloroquine resistance alleles in malaria endemic countries: a systematic review of burden and risk factors. Malar J. 2019;18(1):76. Published 2019 Mar 12. doi:10.1186/s12936-019-2716-z.
Okell LC, Griffin JT, Roper C. Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa. Sci Rep. 2017;7(1):7389. Published 2017 Aug 7. doi:10.1038/s41598-017-06708-9.
Omar SA, Adagu IS, Warhurst DC. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg. 2001;95:315–319. doi: 10.1016/S0035-9203(01)90250-0.
Oyola, S. O., Ariani, C. V., Hamilton, W. L., Kekre, M., Amenga-Etego, L. N., Ghansah, A., ... & Jacob, C. G. (2016). Whole genome sequencing of Plasmodium falciparum from dried blood spots using selective whole genome amplification. Malaria journal, 15(1), 597.
PEEP, 2020. Plano nacional de Eliminação do Paludismo em Cape Verde, 2020-2024. Programa Nacional de Controlo de Doenças de Transmissão e Problemas de Saúde Ambiental, Ministério da Saúde e da Segurança Social. Cape Verde.
Ravenhall M, Benavente ED, Mipando M, et al. Characterizing the impact of sustained sulfadoxine/pyrimethamine use upon the Plasmodium falciparum population in Malawi. Malar J. 2016;15(1):575. Published 2016 Nov 29. doi:10.1186/s12936-016-1634-6.
Ravenhall M, Benavente ED, Sutherland CJ, Baker DA, Campino S, Clark TG. An analysis of large structural variation in global Plasmodium falciparum isolates identifies a novel duplication of the chloroquine resistance associated gene. Sci Rep. 2019;9(1):8287. Published 2019 Jun 4. doi:10.1038/s41598-019-44599-0.
Sisowath C, Petersen I, Veiga MI, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009;199(5):750–757. doi:10.1086/596738.
Somé AF, Séré YY, Dokomajilar C, et al. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother. 2010;54(5):1949–1954. doi:10.1128/AAC.01413-09.
Sondo P, Derra K, Tarnagda Z, et al. Dynamic of plasmodium falciparum chloroquine resistance transporter gene Pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso. Pan Afr Med J. 2015;21:101. Published 2015 Jun 9. doi:10.11604/pamj.2015.21.101.6437.
Staedke SG, et al. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health. 2004;9:624–629. doi: 10.1111/j.1365-3156.2004.01239.x.
Sutherland CJ, Haustein T, Gadalla N, Armstrong M, Doherty JF, Chiodini PL. Chloroquine-resistant Plasmodium falciparum infections among UK travellers returning with malaria after chloroquine prophylaxis. J Antimicrob Chemother. 2007 Jun;59(6):1197-9. Epub 2007 May 2. PubMed PMID: 17475629.
Tacoli C, Gai PP, Bayingana C, Sifft K, Geus D, Ndoli J, et al. Artemisinin resistance-associated K13 polymorphisms of Plasmodium falciparum in Southern Rwanda, 2010–2015. Am J Trop Med Hyg. 2016;95:1090–3.
Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015;211:680–8.
Tumwebaze P, Conrad MD, Walakira A, et al. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children. Antimicrob Agents Chemother. 2015;59(6):3018–3030. doi:10.1128/AAC.05141-14.
Uhlemann AC, McGready R, Ashley EA, Brockman A, Singhasivanon P, Krishna S, White NJ, Nosten F, Price RN. Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. J Infect Dis. 2007;195:134–141. doi: 10.1086/509809.
Van Hong N, Amambua-Ngwa A, Tuan NQ, do Cuong D, Giang NT, Van Dung N, et al. Severe malaria not responsive to artemisinin derivatives in man returning from Angola to Vietnam. Emerg Infect Dis. 2014;20:1199–1202. doi: 10.3201/eid2006.131508.
Veiga MI, Dhingra SK, Henrich PP, et al. Globally prevalent Pfmdr1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nat Commun. 2016;7:11553. Published 2016 May 18. doi:10.1038/ncomms11553.
Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether–lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833–43.
Voumbo-Matoumona DF, Kouna LC, Madamet M, Maghendji-Nzondo S, Pradines B, Lekana-Douki JB. Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014. Infect Drug Resist. 2018;11:1329–1338. Published 2018 Aug 28. doi:10.2147/IDR.S160164.
Wilairatana P, Tangpukdee N, Krudsood S. Definition of hyperparasitemia in severe falciparum malaria should be updated. Asian Pac J Trop Biomed. 2013 Jul;3(7):586. doi: 10.1016/S2221-1691(13)60119-7.
World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 1990; 94(Suppl 1): S1-S33.
World Health Organization. Eliminating Malaria. Case-study 2. Moving towards sustainable elimination in Cape Verde. Geneva, 2012.
World Health Organization, 2014. WHO. Minutes of the Expert Review Committee on K13 molecular marker of artemisinin resistance. Geneva: World Health Organization; 2014.
World Health Organization. Global technical strategy for malaria 2016-2030. World Health Organization, 2015.
World Health Organization, 2019. World Malaria Report 2019.
Yang C, Zhang H, Zhou R, Qian D, Liu Y, Zhao Y, et al. Polymorphisms of Plasmodium falciparum k13-propeller gene among migrant workers returning to Henan Province, China from Africa. BMC Infect Dis. 2017;17:560.